CSTL
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq).Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
Castle Biosciences, Inc. (CSTL) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | C (2.3) | B (3.5) | A- (3.9) | C+ (2.6) | B- (3.0) |
| 2026-11-04 | B- (3.0) | C+ (2.5) | B (3.5) | A- (4.0) | C+ (2.7) | B- (3.1) |
| 2026-10-28 | B- (3.0) | C (2.5) | B (3.5) | A (4.2) | C+ (2.7) | B (3.2) |
| 2026-10-21 | B- (3.0) | C (2.5) | B (3.5) | A- (4.1) | C+ (2.6) | B- (3.1) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe